Goldman Sachs maintains Buy on AMEC's advanced SPE tools and comprehensive platform expansion

Overview

This report is Goldman Sachs' company research on AMEC's 4Q25 results and platform expansion progress. The key conclusion is that AMEC's revenue and gross margin were broadly in line with expectations; short-term operating profit was affected by R&D spending, but the company's push into a comprehensive platform across etching, deposition, metrology, CMP, and Micro LED MOCVD should expand its addressable market and benefit from higher spending on advanced nodes.

Core views

Goldman Sachs maintains a positive view on AMEC and its Buy rating. Supporting factors include the launch of advanced SPE tools, the upgrade of the product mix toward advanced-node demand, the planned acquisition of CMP supplier Hangzhou Sizonetech to enter a larger market, and accelerated shipments of advanced tools. The near-term blemish is that higher-than-expected R&D spending led 4Q25 operating profit to miss estimates, but revenue, gross margin, and net profit remained solid.

Analysis framework

The report compares 4Q25 revenue, gross margin, operating profit, and net profit with Goldman Sachs' estimates and company guidance, assesses the impact of new-product launches, the proposed acquisition, and product-line expansion on future revenue, and uses a discounted P/E approach to derive a 12-month target price.

Methodology notes

• Valuation methodsDiscounted P/E

  43.5x 2029E P/E discounted to 2026E

  Goldman Sachs uses a 43.5x 2029E P/E target multiple and discounts it back to 2026E using an 11% cost of equity to derive a 12-month target price of Rmb462. The target multiple is based on the correlation between global peers' 2026E P/E and their 2026-27E net income growth.

• Factor frameworkGS Factor Profile

  Growth, financial returns, valuation multiples, and composite percentile

  Goldman Sachs' factor framework compares stocks' characteristics versus the market and industry peers across growth, financial returns, valuation multiples, and a composite measure; this report discloses the methodology, but the main investment conclusion is driven primarily by earnings, product expansion, and valuation analysis.

• M&A frameworkM&A Rank

  Potential acquisition probability score

  Goldman Sachs discloses its M&A Rank methodology for globally covered stocks, which classifies acquisition probability into three levels; this factor is not shown as a primary driver of AMEC's target price in this report.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• AMEC (688012.SS)

  The research subject; Goldman Sachs maintains a Buy rating and raises the 12-month target price to Rmb462.

  Strengths

  Product lineup expands from etching into deposition, metrology, CMP, and Micro LED MOCVD; accelerated shipment of advanced tools; 4Q25 revenue and gross margin were broadly in line with expectations.

  Weaknesses

  4Q25 operating profit was 19% below Goldman Sachs' estimate because R&D spending was higher than expected.

  Comparison

  The target multiple references the relationship between global peers' P/E and EPS or net income growth, reflecting AMEC's valuation positioning relative to peers on long-term EPS growth.

  Risks

  Widening trade restrictions, disruptions to supply capability for advanced-node tools, and weaker-than-expected capex by major Chinese wafer fabs.

• Hangzhou Sizonetech (private)

  A CMP supplier in which AMEC plans to acquire a 64.69% stake.

  Strengths

  Should help AMEC enter or strengthen the CMP tools market and expand its addressable market.

  Weaknesses

  The transaction is still only planned disclosure; the report provides no details on integration progress, earnings contribution, or synergies.

  Comparison

  Serves as a CMP supplier complement to AMEC's existing etching, deposition, and metrology platform layout.

  Risks

  Uncertainty remains around deal execution, integration, product ramp-up, and customer validation.

Key data

• 4Q25 revenueRmb4.3bnUp 21% year over year and 39% quarter over quarter, in line with Goldman Sachs' expectations and company guidance.
• 4Q25 gross margin39.3%Improved from 37.9% in 3Q25 and was broadly in line with Goldman Sachs' 39.7% estimate.
• 4Q25 operating profit19% below Goldman Sachs' estimateMainly due to higher-than-expected R&D spending on new products.
• 4Q25 net profitRmb900mSupported by higher non-operating income, 2% above Goldman Sachs' estimate.
• 2027/28E earnings revisions+1% / +1%Mainly driven by higher revenue assumptions for etching, deposition, and metrology tools, with gross margin and expense ratios largely unchanged.
• Proposed acquisitionAcquire 64.69% of Hangzhou Sizonetech for about Rmb1.6bnThe target is a CMP supplier, which should help expand AMEC's addressable market.
• Target priceRmb462Previously Rmb459; Buy maintained.
• Valuation assumption43.5x 2029E P/E, 11% COEThe target P/E multiple is unchanged and is discounted back to 2026E.

Impact & implications

The report is positively tilted on AMEC from an investment perspective: platform expansion and advanced-node tool upgrades could enlarge long-term revenue potential, and the CMP acquisition plan should help fill out the product portfolio; near term, investors should watch the pressure from R&D spending on margins and operating profit, as well as volatility in advanced-node demand and Chinese wafer fab capex.

Risks

• Although existing trade restrictions are not explicitly aimed at mature-node wafer fabs, further expansion of restrictions to mature nodes could weaken demand for AMEC's products.
• AMEC supplies etchers that can be used on overseas 5nm production lines; if its ability to supply such advanced-node products is constrained, this could create downside risk.
• Capex by major Chinese wafer fabs is weaker than expected.
• R&D spending staying above expectations could continue to pressure operating profit.

What to watch

• Shipment cadence and customer validation progress for advanced etching, deposition, and metrology tools.
• Approval, closing, and integration progress for the Hangzhou Sizonetech acquisition.
• The actual revenue and gross margin contribution from the CMP tools business.
• Changes in capex by major Chinese wafer fabs.
• Whether trade restrictions expand from advanced nodes to mature nodes.
• Whether the R&D expense ratio stabilizes as new products ramp.